Skip to content
Top Globe News – Lifestyle
Author:
LB Pharmaceuticals Inc
LB Pharmaceuticals to Participate in Upcoming June Investor Events
May 28, 2026
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
April 29, 2026
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
March 27, 2026
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
March 26, 2026
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
March 25, 2026